2020 Genitourinary Cancers Symposium

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Moscone West Building
San Francisco, CA, United States
Feb 13, 2020 - Feb 15, 2020
Visit the conference website for more details.

Expert Opinion

featured

Robotic Cystectomy in Bladder Cancer

Interview · February 27, 2020

ASCO GU
featured

Time to Second Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide

Interview · February 27, 2020

ASCO GU
featured

Nintedanib With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Bladder Cancer

Interview · February 27, 2020

ASCO GU
featured

Future Directions for PARP Inhibitors in Metastatic Urothelial Carcinoma

Interview · February 26, 2020

ASCO GU
featured

Health-Related Quality of Life Outcomes With Retropubic Versus Robotic Prostatectomy

Interview · February 26, 2020

ASCO GU
featured

Neoadjuvant Therapy for Locally Advanced Prostate Cancer

Interview · February 26, 2020

ASCO GU
featured

Dose-Dense MVAC Versus Gemcitabine/Cisplatin for Preoperative Treatment of Muscle-Invasive Bladder Cancer

Interview · February 25, 2020

ASCO GU
featured

Important Bladder Cancer Studies at ASCO GU 2020

Interview · February 25, 2020

ASCO GU
featured

Nivolumab, Gemcitabine, and Cisplatin for Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy

Interview · February 25, 2020

ASCO GU
featured

Durvalumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

Interview · February 25, 2020

ASCO GU

News

ASCO GU 2020: Patients With Testicular Cancer Harbor a High Percentage of Hereditary Cancer Gene Mutations

PracticeUpdate Editorial Team · February 24, 2020

ASCO GU
ASCO GU 2020: VEGF Tyrosine Kinase Inhibitors Show Activity After Combination Immunotherapy for Metastatic Renal Cell Carcinoma

PracticeUpdate Editorial Team · February 24, 2020

ASCO GU
ASCO GU 2020: A Novel GnRH Antagonist Formulation Leads to Undetectable Testosterone for ≥6 Months in an Animal Model

PracticeUpdate Editorial Team · February 24, 2020

ASCO GU
ASCO GU 2020: A Next-Generation Aniten Compound Shows Promise Against Prostate Cancer

PracticeUpdate Editorial Team · February 24, 2020

ASCO GU
ASCO GU 2020: Circulating Ensembles of Tumor-Associated Cells Are Detected Ubiquitously in Kidney, Bladder, and Prostate Cancers

PracticeUpdate Editorial Team · February 21, 2020

ASCO GU
ASCO GU 2020: Cytoreductive Nephrectomy Linked With Longer Overall Survival in Patients Treated With Immune Checkpoint Inhibition or Targeted Therapy for Metastatic Renal Cell Carcinoma

PracticeUpdate Editorial Team · February 21, 2020

ASCO GU
ASCO GU 2020: Factors Are Identified That Underlie the Seeking of Palliative Care by Patients With Genitourinary Malignancies

PracticeUpdate Editorial Team · February 20, 2020

ASCO GU
ASCO GU 2020: Response Rates and Survival Remain Superior with Nivolumab Over Everolimus >5 Years in Advanced Renal Cell Carcinoma

PracticeUpdate Editorial Team · February 19, 2020

ASCO GU
ASCO GU 2020: Tumor p16 Status Is an Independent Prognostic Factor for Cancer-Specific Survival in Penile Squamous Cell Carcinoma

PracticeUpdate Editorial Team · February 19, 2020

ASCO GU
ASCO GU 2020: Pembrolizumab + Olaparib Continues to Show Promise in Molecularly Unselected Metastatic Castrate-Resistant Prostate Cancer

PracticeUpdate Editorial Team · February 19, 2020

ASCO GU

2020 Genitourinary Cancers Symposium

Expert Opinion

Robotic Cystectomy in Bladder Cancer

Time to Second Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide

Nintedanib With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Bladder Cancer

Future Directions for PARP Inhibitors in Metastatic Urothelial Carcinoma

Health-Related Quality of Life Outcomes With Retropubic Versus Robotic Prostatectomy

Neoadjuvant Therapy for Locally Advanced Prostate Cancer

Dose-Dense MVAC Versus Gemcitabine/Cisplatin for Preoperative Treatment of Muscle-Invasive Bladder Cancer

Important Bladder Cancer Studies at ASCO GU 2020

Nivolumab, Gemcitabine, and Cisplatin for Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy

Durvalumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer

News

ASCO GU 2020: Patients With Testicular Cancer Harbor a High Percentage of Hereditary Cancer Gene Mutations

ASCO GU 2020: VEGF Tyrosine Kinase Inhibitors Show Activity After Combination Immunotherapy for Metastatic Renal Cell Carcinoma

ASCO GU 2020: A Novel GnRH Antagonist Formulation Leads to Undetectable Testosterone for ≥6 Months in an Animal Model

ASCO GU 2020: A Next-Generation Aniten Compound Shows Promise Against Prostate Cancer

ASCO GU 2020: Circulating Ensembles of Tumor-Associated Cells Are Detected Ubiquitously in Kidney, Bladder, and Prostate Cancers

ASCO GU 2020: Cytoreductive Nephrectomy Linked With Longer Overall Survival in Patients Treated With Immune Checkpoint Inhibition or Targeted Therapy for Metastatic Renal Cell Carcinoma

ASCO GU 2020: Factors Are Identified That Underlie the Seeking of Palliative Care by Patients With Genitourinary Malignancies

ASCO GU 2020: Response Rates and Survival Remain Superior with Nivolumab Over Everolimus >5 Years in Advanced Renal Cell Carcinoma

ASCO GU 2020: Tumor p16 Status Is an Independent Prognostic Factor for Cancer-Specific Survival in Penile Squamous Cell Carcinoma

ASCO GU 2020: Pembrolizumab + Olaparib Continues to Show Promise in Molecularly Unselected Metastatic Castrate-Resistant Prostate Cancer

No Content

Recently Updated